Sanofi (SNY) Upgraded to “Buy” by BidaskClub

Sanofi (NYSE:SNY) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Friday.

A number of other research firms have also weighed in on SNY. Berenberg Bank lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Friday, June 2nd. Argus raised their target price on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, June 9th. TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. Finally, J P Morgan Chase & Co reissued a “sell” rating on shares of Sanofi in a research note on Wednesday, April 5th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company’s stock. Sanofi presently has an average rating of “Hold” and an average target price of $67.67.

Analyst Recommendations for Sanofi (NYSE:SNY)

Shares of Sanofi (NYSE SNY) traded down 0.83% during midday trading on Friday, hitting $49.20. The stock had a trading volume of 3,605,638 shares. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The stock has a market cap of $124.25 billion, a PE ratio of 12.16 and a beta of 0.93. The firm has a 50 day moving average price of $48.82 and a 200-day moving average price of $44.16.

Sanofi (NYSE:SNY) last released its earnings results on Friday, April 28th. The company reported $0.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.03. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The business had revenue of $8.65 billion for the quarter, compared to analyst estimates of $8.40 billion. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. Equities analysts predict that Sanofi will post $3.15 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by sleekmoney and is owned by of sleekmoney. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://sleekmoney.com/sanofi-sny-upgraded-to-buy-by-bidaskclub/1935290.html.

Several hedge funds have recently made changes to their positions in SNY. Russell Investments Group Ltd. purchased a new stake in shares of Sanofi during the fourth quarter worth about $1,606,000. Guggenheim Capital LLC increased its stake in shares of Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock worth $872,000 after buying an additional 311 shares in the last quarter. Dodge & Cox purchased a new stake in shares of Sanofi during the fourth quarter worth about $2,770,485,000. Cullinan Associates Inc. increased its stake in shares of Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock worth $2,896,000 after buying an additional 3,340 shares in the last quarter. Finally, Manning & Napier Advisors LLC increased its stake in shares of Sanofi by 8.0% in the first quarter. Manning & Napier Advisors LLC now owns 244,282 shares of the company’s stock worth $11,052,000 after buying an additional 18,094 shares in the last quarter. Institutional investors and hedge funds own 9.84% of the company’s stock.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/sanofi-sny-upgraded-to-buy-by-bidaskclub/1935290.html

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *